Production of biologic active ingredients at the site is scheduled to start in 2026. Part of the Limerick site's production capacity has been earmarked for donanemab, which was approved by the US ...

Eli Lilly has reported the results of its much-anticipated phase 3 trial of amyloid-targeting Alzheimer’s disease therapy donanemab, saying that almost half the patients treated with the drug ...

The United Kingdom medicines authority approved the Alzheimer’s disease drug Kisunla (donanemab) last week for certain patients. This follows the Unites States Food and Drug Administration ...